Antihypertensive Pharmacotherapy in Chronic Kidney Disease: Integrating eGFR-Based Cutoffs, Mechanistic Insights, and Emerging Therapeutic Pathways

Clicks: 15
ID: 328322
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #78 of 87 articles by views in American Journal of Hypertension

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Optimal hypertension management requires not only stringent blood pressure control but also concomitant management of related cardiovascular, metabolic, and kidney comorbidities. Emerging evidence demonstrates that contemporary therapies improve albuminuria, estimated glomerular filtration rate trajectory, kidney outcomes, and cardiovascular outcomes, although the relative contributions of sustained blood pressure reduction and other biologic effects cannot always be separated. This review examines the impact of current and emerging treatment strategies across three core domains: blood pressure control, kidney function trajectory, and albuminuria reduction. Emphasis is placed on kidney function-based treatment selection, safety considerations including advanced disease, the role of targeted therapy in dysregulated aldosterone states, and evolving options for resistant hypertension. A risk- and clinical-characteristic-guided approach that integrates kidney stage, degree of albuminuria, and overall cardiovascular risk is proposed to move beyond uniform drug escalation toward personalized care. Early risk stratification, thoughtful sequencing, and structured monitoring are essential to translate therapeutic advances into sustained kidney and cardiovascular benefit.
Reference Key
openalex_W7212078962 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sriram Sriperumbuduri, Rachel W. Khan, Soyeb Aftab, Swapnil Hiremath, Dave Dixon, Gaurav Gupta
Are you one of these authors? Claim your profile
Journal American Journal of Hypertension
Year 2026
DOI
10.1093/ajh/hpag111
URL
https://doi.org/10.1093/ajh/hpag111
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.